porcin
epidem
diarrhea
viru
pedv
circul
throughout
europ
asia
past
three
decad
detect
swine
unit
state
may
sinc
introduct
us
pedv
identifi
state
nation
anim
health
laboratori
network
decemb
wwwaasvorg
character
wateri
diarrhea
vomit
dehydr
high
mortal
rate
suckl
pig
us
pedv
strain
phylogenet
subgroup
iia
similar
pedv
circul
asia
modifiedl
vaccin
mlv
long
use
asia
control
pedv
strain
attenu
onehundr
cell
cultur
passag
subgroup
isol
licens
japan
attenu
live
pedv
vaccin
attenu
process
strain
acquir
fourteen
amino
acid
chang
immunodomin
spike
protein
critic
viru
bind
cell
receptor
target
neutral
antibodi
live
attenu
vaccin
strain
pedv
whose
parent
strain
subgroup
ii
thirteen
fourteen
mutat
well
subsequ
cluster
subgroup
serial
passag
vero
cell
result
attenu
virul
vivo
strong
select
viral
spike
gene
associ
phenotyp
chang
classic
attenu
cell
cultur
passag
pedv
also
show
mutat
open
read
frame
orf
chang
restrict
fragment
length
polymorph
rflp
cut
pattern
use
distinguish
mlv
field
strain
vivo
highpassag
x
mlv
attenu
sow
piglet
still
capabl
induc
robust
immun
respons
attenu
abil
caus
diseas
safeti
use
mlv
question
mlv
shed
environ
viru
detect
fece
old
piglet
seven
day
oral
inocul
passag
pedv
isol
diarrheic
pig
china
close
phylogenet
relationship
two
mlv
vaccin
suggest
may
evolv
mlv
modifi
live
vaccin
gener
elicit
robust
protect
immun
respons
inactiv
viru
vaccin
longterm
efficaci
often
lack
due
viral
mutat
accompani
antigen
chang
late
china
experienc
sever
outbreak
pedv
suckl
pig
caus
drastic
econom
loss
outbreak
caus
strain
phylogenet
distinct
gene
chines
strain
vaccin
strain
pedv
infect
rate
vaccin
herd
china
increas
dramat
phylogenet
analysi
new
variant
outbreak
show
insert
delet
antigen
region
gene
may
influenc
efficaci
mlv
investig
whether
inactiv
vaccin
elicit
protect
immun
respons
could
lead
develop
vaccin
close
relat
field
strain
avoid
potenti
antigen
chang
due
excess
vitro
cultiv
current
two
condit
licens
pedv
vaccin
us
label
claim
use
sow
inactiv
viru
vaccin
alphaviru
vector
subunit
vaccin
mortal
rate
high
suckl
piglet
total
loss
estim
million
anim
us
less
one
year
pedv
vaccin
critic
need
wwwaasvorg
us
depart
agricultur
usda
allow
product
autogen
vaccin
address
emerg
diseas
howev
difficulti
isol
pedv
cell
cultur
increas
difficulti
produc
efficaci
inactiv
vaccin
pedv
isol
pool
intestin
homogen
passag
cell
cultur
inactiv
cell
cultur
deriv
viral
vaccin
immunogen
administ
pig
knowledg
first
demonstr
immunogen
inactiv
us
pedv
vaccin
trial
pig
us
swine
studi
perform
newport
laboratori
approv
newport
laboratori
institut
anim
care
use
committe
may
intestin
pig
iowa
experienc
pedvlik
symptom
submit
newport
laboratori
diagnost
test
intestin
homogen
phosphat
buffer
salin
debri
remov
centrifug
g
minut
follow
filtrat
filter
viru
isol
perform
vero
vero
cell
cell
maintain
dulbecco
modif
eagl
medium
dmem
five
percent
fetal
bovin
serum
one
percent
lglutamin
confluent
monolay
wash
three
time
dmem
without
serum
prior
inocul
initi
infect
cell
plate
inoculum
adsorb
hour
small
amount
viral
growth
media
dmem
chloromethyl
keton
tpck
treat
trypsin
antibiot
invivogen
inoculum
rins
plate
viral
growth
media
cell
refe
viral
growth
media
plate
incub
day
frozen
thaw
passag
subsequ
passag
perform
inocul
cell
cultur
harvest
onto
confluent
monolay
plate
viral
replic
verifi
real
time
revers
transcript
polymeras
chain
reaction
rtrtpcr
indirect
immunofluoresc
ifa
viral
cultur
scale
flask
roller
bottl
result
npl
pedv
ifa
perform
vero
monolay
infect
well
fix
cold
ethyl
alcohol
polyclon
rabbit
antipedv
nucleoprotein
np
antiserum
south
dakota
state
univers
anim
diseas
research
diagnost
laboratori
sdsu
ad
cell
rins
incub
fluorescein
isothiocyan
fitc
label
goat
antirabbit
igg
jackson
immunoresearch
dilut
read
use
fluoresc
microscop
tissu
cultur
infect
dose
calcul
use
spearmankarb
method
viral
rna
cell
cultur
passag
extract
use
viral
rna
isol
kit
life
technolog
accord
manufactur
instruct
rtrtpcr
perform
use
qiagen
rtpcr
follow
pedv
primer
probe
pedv
forward
acg
tcc
gta
aca
cct
tca
ag
pedv
revers
gct
agt
gcc
tgt
acc
ata
gat
pedv
probe
cgt
gcc
agt
aat
caa
ctc
acc
ctt
tgt
analyt
purpos
neg
sampl
assign
ct
valu
correspond
detect
limit
method
approxim
method
specif
assess
use
variou
porcin
enter
virus
includ
transmiss
gastroenter
viru
group
rotaviru
porcin
enteroviru
crossreact
observ
standard
curv
gener
serial
dilut
cell
harvest
contain
pedv
determin
titrat
cell
cell
show
cytopath
effect
cpe
follow
viru
infect
passag
x
use
rna
extract
sequenc
ml
cell
cultur
supernat
filter
use
bottl
top
filter
thermo
scientif
lenexa
kansa
filtrat
centrifug
g
hour
supernat
discard
pellet
suspend
water
sampl
concentr
final
volum
use
ultra
centrifug
filter
ml
millipor
tullagreen
ireland
cellular
dna
rna
remov
incub
dnase
unit
new
england
biolab
neb
ipswich
rnase
qiagen
valencia
ca
hour
rna
extract
use
ls
reagent
life
technolog
grand
island
ny
accord
manufactur
instruct
pellet
contain
rna
resuspend
steril
total
rna
deplet
ribosom
rna
use
rrna
deplet
kit
qiagen
rna
sequenc
librari
gener
use
ion
total
rnaseq
kit
ion
life
technolog
accord
manufactur
instruct
sequenc
carri
use
ion
person
genom
pgm
sequenc
platform
life
technolog
grand
island
ny
previous
describ
sequenc
read
assembl
contig
use
ngen
program
dnastar
madison
wi
phylogenet
analysi
full
genom
sequenc
perform
use
softwar
use
maximum
likelihood
analysi
bootstrap
replic
verifi
tree
topolog
sequenc
align
perform
use
clustalw
algorithm
megalign
dnastar
madison
wi
complet
genom
npl
pedv
compar
sequenc
deriv
origin
clinic
sampl
genbank
variou
refer
strain
refer
strain
includ
genbank
belgium
attenu
genbank
virul
genbank
genbank
south
korea
lzc
genbank
genbank
ch
genbank
china
genbank
mn
genbank
variant
strain
genbank
unit
state
genom
sequenc
npl
pedv
deposit
genbank
access
number
genbank
swine
vaccin
studi
approv
institut
biosafeti
committe
institut
anim
care
use
committe
iacuc
guidelin
studi
perform
newport
laboratori
biosafeti
level
sixti
pig
approxim
week
age
obtain
commerci
highhealth
herd
mix
sex
crossbr
american
yorkshirelandraceduroc
prior
studi
commenc
pig
verifi
serolog
neg
pedv
ffn
ifa
pig
also
neg
pedv
shed
rtrtpcr
fecal
swab
pig
divid
vaccin
group
pig
nonvaccin
control
group
pig
comingl
among
two
differ
room
pig
allow
week
acclim
prior
studi
commenc
viru
npl
pedv
inactiv
concentr
use
vaccin
inactiv
perform
addit
binari
ethyleneimin
bei
final
volum
incub
hour
excess
bei
neutral
sodium
thiosulf
viru
inactiv
verifi
passag
inactiv
fluid
three
time
permiss
cell
result
evid
cpe
increas
rtrtpcr
titer
concentr
perform
use
hollow
fiber
filter
spectrum
lab
due
space
constraint
number
studi
group
vaccin
group
receiv
antigen
consist
pig
group
receiv
lower
level
antigen
anticip
show
robust
immun
respons
tabl
group
vaccin
intramuscularli
im
neck
ml
respect
inactiv
viru
group
vaccin
im
neck
ml
respect
inactiv
viru
treat
ad
incub
room
temperatur
minut
sigma
group
vaccin
rear
flank
inactiv
viru
inactiv
viru
treat
respect
done
evalu
potenti
chang
immun
respons
due
chang
vaccin
site
vaccin
formul
contain
proprietari
oil
water
adjuv
pig
vaccin
day
observ
advers
vaccin
reaction
one
hour
anim
also
observ
daili
sign
diseas
serum
collect
day
studi
termin
day
fecal
swab
collect
three
day
post
vaccin
test
rtrtpcr
confirm
absenc
pedv
shed
fluoresc
foci
neutral
assay
ffn
perform
sdsu
use
nation
veterinari
servic
laboratori
nvsl
refer
isol
briefli
test
control
serum
sampl
heat
inactiv
minut
serial
dilut
serumfre
modifi
eagl
medium
mem
contain
tpck
treat
trypsin
plate
final
volum
next
pedv
stock
dilut
fluoresc
focu
unit
ffu
ad
well
plate
incub
hour
plate
contain
confluent
day
old
monolay
cell
wash
time
serumfre
mem
prior
transfer
serumviru
mixtur
correspond
well
plate
hour
incub
serumviru
mixtur
remov
monolay
wash
serumfre
mem
replac
media
mem
tpck
treat
trypsin
ad
well
plate
incub
hour
monolay
fix
minut
aceton
water
dri
stain
fluorescein
conjug
pedv
antinucleoprotein
np
monoclon
antibodi
titer
report
reciproc
greatest
serum
dilut
result
greater
reduct
ffu
rel
viru
control
well
ffn
titer
consid
neg
enzymelink
immunosorb
assay
elisa
perform
univers
minnesota
umn
veterinari
diagnost
laboratori
assay
util
recombin
pedv
np
antigen
sampl
sampl
posit
ratio
sp
valu
greater
consid
posit
experiment
elisa
use
recombin
pedv
np
also
perform
sdsu
verifi
umn
result
sdsu
cutoff
posit
result
sp
accord
roc
analysi
use
medcalc
softwar
unpublish
confer
proceed
elisa
detect
swine
igg
investig
immun
respons
inactiv
pedv
vaccin
fluoresc
microspher
immunoassay
fmia
perform
sdsu
use
purifi
fulllength
kda
pedv
nucleoprotein
antigen
use
elisa
briefli
full
length
nucleocapsid
open
read
frame
pedv
clone
prokaryot
express
vector
novagen
recombin
protein
express
histag
fusion
protein
purifi
use
ninta
agaros
column
chromatographi
prior
fluoresc
microspher
coupl
fmia
perform
previous
describ
coupl
microspher
analyz
duallas
biorad
bioplex
instrument
mean
fluoresc
intens
mfi
microspher
correspond
individu
bead
analyt
record
well
report
mfi
measur
normal
via
f
background
signal
determin
fluoresc
measur
test
sampl
uncoat
bead
f
mfi
serolog
test
sampl
antigenco
bead
statist
analysi
perform
use
spss
softwar
oneway
anova
tukey
hsd
perform
group
use
harmon
mean
sampl
size
account
unequ
group
size
also
comparison
group
titer
viru
differ
treatment
done
ttest
rtrtpcr
ct
valu
pedv
posit
intestin
homogen
initi
isol
attempt
vero
vero
cell
line
passag
sampl
continu
vero
cell
viral
replic
evid
rtrtpcr
cpe
evid
two
passag
confirm
pedv
rtrtpcr
ifa
ct
valu
passag
x
x
rang
cultur
scale
vero
flask
x
ct
cell
cultur
adapt
cell
x
ct
x
ct
due
usdalicens
statu
autogen
vaccin
product
two
passag
flask
cultur
scale
roller
bottl
cell
passag
x
ct
titer
determin
ifa
isol
pedv
design
npl
pedv
phylogenet
analysi
complet
genom
sequenc
show
ident
us
pedv
viru
genbank
origin
intestin
sampl
genbank
minnesota
isol
genbank
isol
ohio
genbank
also
close
relat
npl
strain
figur
envelop
e
membran
np
gene
eleven
ped
refer
virus
align
percent
nucleotid
ident
npl
determin
tabl
show
greatest
diverg
nucleotid
ident
gene
next
diverg
nucleotid
ident
amongst
us
strain
e
np
highli
conserv
greater
nucleotid
ident
gene
show
greatest
variabl
amongst
us
strain
ident
npl
pedv
pig
studi
confirm
seroneg
pedv
antibodi
day
ifa
ffn
data
shown
pig
fecal
swab
collect
day
post
vaccin
neg
pedv
confirm
infecti
pedv
present
vaccin
advers
reaction
note
follow
vaccin
day
vaccin
group
posit
mean
titer
ffn
tabl
post
hoc
analysi
ffn
result
show
group
along
treat
group
group
statist
signific
higher
mean
ffn
titer
control
group
p
level
signific
differ
mean
compar
per
tukey
hsd
group
statist
similar
control
group
tukey
hsd
analysi
use
harmon
mean
sampl
size
due
unequ
group
size
ttest
also
perform
group
titer
viru
differ
treatment
tabl
statist
differ
ffn
titer
vaccin
group
titer
without
treatment
ffn
assay
one
anim
group
inactiv
treat
viru
rear
flank
show
posit
elisa
result
umn
data
shown
clarifi
result
elisa
test
perform
sdsu
result
support
umn
result
antinucleoprotein
antibodi
treat
group
recogn
elisa
result
show
highli
signific
increas
sp
ratio
inactiv
viru
im
neck
rear
flank
group
respect
compar
control
group
umn
sdsu
assay
tabl
signific
group
tukey
hsd
significantli
higher
result
compar
remain
group
umn
elisa
sdsu
elisa
group
also
significantli
higher
result
group
per
tukey
hsd
ttest
show
signific
differ
elisa
result
group
im
without
respect
well
group
flank
without
respect
also
sdsu
elisa
show
near
signific
differ
group
without
respect
p
valu
fmia
perform
group
im
flank
mfi
valu
significantli
higher
control
tukey
hsd
analysi
tabl
vaccin
group
group
without
statist
higher
mfi
treat
group
ttest
tabl
group
group
statist
lower
mfi
group
significantli
higher
mfi
group
group
mfi
show
differ
treatment
ttest
significantli
higher
control
via
tukey
hsd
probabl
due
low
antibodi
titer
level
result
indic
treatment
creat
signific
differ
elisa
fmia
assay
result
affect
ffn
result
sever
diseas
caus
outbreak
pedv
make
imper
efficaci
vaccin
develop
due
difficulti
vitro
cultiv
high
viru
transmiss
lead
biosecur
concern
limit
research
perform
pig
us
four
percent
success
rate
viru
isol
report
develop
diagnost
test
research
us
field
strain
hamper
success
isol
passag
us
pedv
isol
growth
maintain
cell
genet
character
npl
found
ident
strain
circul
asia
earli
high
genet
homolog
circul
strain
us
make
suitabl
candid
investig
us
pedv
inactiv
vaccin
immunogen
pig
data
publish
regard
efficaci
attenu
mlv
asia
limit
publish
data
immunogen
inactiv
subunit
pedv
vaccin
studi
demonstr
inactiv
pedv
vaccin
immunogen
pig
vaccin
group
studi
design
investig
effect
viru
titer
site
administr
deterg
treatment
antigen
immunogen
pig
dose
respons
observ
ffn
vaccin
contain
differ
viru
titer
group
significantli
greater
group
vaccin
administ
im
rear
flank
determin
site
administr
would
affect
overal
immunogen
respons
flank
vaccin
site
test
group
expect
highest
immun
respons
howev
signific
differ
two
site
administr
likewis
signific
differ
vaccin
formul
treat
antigen
ffn
challeng
model
need
correl
ffn
andor
elisa
titer
protect
surprisingli
except
one
pig
neg
elisa
result
obtain
pig
vaccin
treat
viru
formul
despit
high
ffn
mean
titer
ttest
show
treat
group
significantli
differ
non
treat
group
titer
elisa
fmia
deterg
use
creat
splitvirion
vaccin
influenza
viru
immunogen
nonreactogen
data
suggest
treatment
pedv
antigen
alter
antigen
immunogen
np
lead
neg
elisa
result
immunogen
capabl
induc
neutral
antibodi
respons
detect
ffn
assay
remain
intact
two
elisa
test
fmia
util
np
antigen
treatment
vaccin
may
alter
conform
virion
np
antibodi
induc
antigen
abl
recogn
recombin
np
use
elisa
fmia
assay
ffn
detect
function
neutral
antibodi
associ
epitop
protein
may
better
quantifi
antibodi
respons
treat
virus
elisa
target
protein
readili
avail
may
also
subject
variat
protein
conform
associ
treatment
though
vaccin
trial
abl
gener
antibodi
respons
indic
ffn
fmia
elisa
assay
protect
titer
unknown
previou
work
attenu
viru
use
vaccin
sow
show
immun
respons
elisa
serum
colostrum
could
draw
specif
correl
level
mucos
immun
need
confer
protect
anoth
studi
show
antibodi
detect
serum
piglet
colostrum
pregnant
sow
inocul
attenu
pedv
though
find
specif
protect
antibodi
titer
colostrum
complic
due
vari
factor
includ
litter
size
colostrum
uptak
per
piglet
antibodi
concentr
qualiti
colostrum
due
biosecur
concern
postvaccin
challeng
perform
studi
done
futur
determin
immun
correl
protect
report
farm
reinfect
primari
outbreak
diseas
continu
ongo
problem
due
lack
complet
immun
infect
one
case
piglet
born
reinfect
sow
report
suffer
around
mortal
instead
near
first
outbreak
research
necessari
determin
secondari
outbreak
sow
could
prevent
via
vaccin
booster
studi
focus
humor
immun
respons
sera
vaccin
pig
postvaccin
immun
respons
sow
antibodi
titer
colostrum
studi
optim
vaccin
regimen
would
util
matern
antibodi
protect
pig
suscept
pedv
addit
inactiv
vaccin
may
prove
efficaci
use
booster
conjunct
live
exposur
follow
mlv
risk
reinfect
among
previous
expos
herd
inactiv
vaccin
booster
pregnant
sow
could
reduc
occurr
reinfect
limit
secondari
outbreak
pedv
continu
sourc
econom
loss
continu
profound
impact
swine
market
us
result
demonstr
immunogen
pedv
inactiv
viral
vaccin
us
strain
inform
immunogen
studi
show
potenti
inactiv
vaccin
develop
us
pedv
strain
work
need
evalu
protect
ffn
titer
elisa
fmia
respons
vaccinationchalleng
studi
